How does BioMate AI perform compared to ChatGPT, Gemini, Biomni Lab, and other large language models on bioinformatics, drug discovery, and pharmacokinetics benchmarks? This page reports BioMate’s scores on public evaluation suites alongside published competitor results — so you can compare directly.
BioMate vs. AI Systems at a Glance
All scores from internal benchmarks using published evaluation methodologies. Competitor scores from published papers cited in each section below.
General-purpose large language models — including ChatGPT, Claude, and Gemini — hallucinate bioinformatics code and pipeline parameters at high rates when given free-form research requests. Independent studies (VirBench, Anthropic 2026; Robin/FutureHouse, Nature 2026) confirm that the execution gap between what an LLM claims to do and what it actually runs correctly is the central bottleneck in AI-assisted biology.
BioMate closes this gap through deterministic workflow grounding: every LLM response is checked against a validated index of 4,000+ real bioinformatics pipelines (nf-core, Bioconductor, GATK, CryoSPARC, AlphaFold) before execution. Parameters are extracted using a hybrid rule + LLM architecture validated at 84.8% accuracy. Results run on AWS Batch with quantitative QC gates — not generated as text that may or may not run.
Each page covers methodology, raw numbers, competitor comparisons, and context for interpreting what the scores mean for real research workloads.
How accurately does BioMate select the right pipeline from 4,000+ options across 36 biomedical domains? How does it compare to Biomni Lab on BixBench? How well does it read parameters from plain language?
How accurate is BioMate’s ADMET property prediction across Lipinski, hERG, BBB, and CYP? How does the PBPK engine validate against FDA reference compounds? What is the end-to-end completion rate on drug design workflows?
How does BioMate score on BiomniEval biomedical reasoning questions versus the Biomni-R0-32B-Preview specialist model? How many quantitative QC gates does it enforce? How does auto-remediation work in practice?
In cross-domain routing benchmarks across 120 test cases spanning all 36 biomedical domains, BioMate achieves 94.6% first-pick routing accuracy — exceeding the 80% target. Routing stability is 100% across independent runs (Cohen’s Kappa = 1.0).
On BixBench (205 bioinformatics tasks), BioMate scores 92.7% — outperforming Biomni Lab (88.7%), the closest published competitor using the same evaluation methodology. General-purpose LLMs (ChatGPT, Claude, Gemini) without specialized bioinformatics grounding score significantly lower because they generate code that appears plausible but fails to execute or produces incorrect biological results. BioMate’s edge comes from grounding every task in 15,641 validated Bioconductor workflow steps and running results through quantitative QC gates — not just generating text.
BioMate’s ADMET pipeline achieves 96.3% accuracy across 60 multi-property test cases (v3 benchmark), covering Lipinski filters, hERG cardiotoxicity, BBB permeability, metabolic stability, aqueous solubility, and mutagenicity.
BioMate extracts workflow parameters from natural-language research descriptions at 84.8% accuracy (v10, n=115), up from ~50% baseline using LLM-only extraction. The improvement comes from a hybrid rule + LLM architecture where rules handle unit conversions, boolean flags, and canonical alias normalization, while the LLM handles free-text values.
BioMate’s PBPK simulation achieves a 100% pass rate on 18 pharma-standard reference compounds validated against FDA first-in-human datasets. All predictions fall within the FDA-accepted 2-fold accuracy window.
In a production stability test on AWS Batch (April 2026), BioMate completed 24/24 drug discovery workflows without failure across 7 domains — ADMET screening, molecular docking, PBPK, CYP drug-drug interaction, population PK, BOIN clinical dose escalation, and lead optimisation. A separate auto-loop QC test ran 96/96 cycles successfully across ADMET, CYP-DDI, docking, and NCA-PK domains. These are real Nextflow pipeline executions on cloud compute, not simulated runs.
BioMate applies 20 quantitative QC gates verified end-to-end in AWS Batch production, each with Gold/Silver/Bronze thresholds derived from published community standards including ENCODE, GTEx, nf-core, FDA, and ICH.
| Benchmark | BioMate AI | Best published competitor | Dataset |
|---|---|---|---|
| BixBench bioinformatics (205 tasks) | 92.7% | Biomni Lab — 88.7% | BixBench v36, n=205 |
| ADMET drug property prediction | 96.3% | General LLMs — <70% | Internal v3, n=60 |
| Workflow routing accuracy | 94.6% | — | Internal v11, n=120, 36 domains |
| Parameter extraction from plain language | 84.8% | LLM-only baseline — ~50% | Internal v10, n=115 |
| PBPK pharmacokinetics (FDA 2-fold window) | 100% pass rate | — | 18 pharma compounds, FDA FIH 2005 |
| Drug design E2E execution (AWS Batch) | 24/24 pass | — | Runs 12861–12884, April 2026, 7 drug-dev domains |
| Auto-loop QC cycles (ADMET/CYP-DDI/Docking/NCA-PK) | 96/96 pass | — | Playwright E2E, April 2026 |
| QC gate coverage (end-to-end verified) | 20 gates | — | AWS Batch production, Gold/Silver/Bronze |
Competitor scores are from published papers cited in each section above. “General LLMs” refers to ChatGPT, Claude, and Gemini used without specialized bioinformatics grounding or workflow execution infrastructure. BioMate scores measured using same evaluation methodology as cited competitors where applicable.
Start with free credits. No infrastructure to configure, no command line required.
Try free →